article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

But not everyone in drug development is playing this game. No wonder investing in drug development is so hard! The single most important skill for investing in drug development, or managing a portfolio of assets in a company, is recognizing when the “switch point” comes for each asset.

article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genetics is a missing link in kidney disease drug development

BioPharma Drive: Drug Pricing

Genetic research is driving progress in kidney disease drug discovery.

Disease 147
article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. Reshaping drug development through CRO/CDMO integration. Integrated CDMO and CRO Services Creates Innovation in Early-Stage Drug Development.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management.

article thumbnail

Accelerate oncology drug development: A data-driven approach to clinical decisions

BioPharma Drive: Drug Pricing

Speed vs. success in oncology trials: Discover data-driven strategies to accelerate drug development.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drug developers may need to reassess their therapeutic strategies. This has led drug developers to unintentionally limit their potential within chosen therapeutic spaces.